Pre-order Enquiry
Request Free Sample
Global Recombinant Human Granulocyte Colony-Stimulating Market Outlook 2022
SKU ID : QYR-19406390 | Publishing Date : 27-Oct-2021
Request Sample
Request Customization
Check Discounts
Granulocyte-colony stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
The global Recombinant Human Granulocyte Colony-Stimulating market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Recombinant Human Granulocyte Colony-Stimulating volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Recombinant Human Granulocyte Colony-Stimulating market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Recombinant Human Granulocyte Colony-Stimulating Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Others
Segment by Application
Chemotherapy Induced Neutropenia
Before Blood Donation
Stem Cell Transplants
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Amgen
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Kyowa Hakko Kirin
Gensci
Amoytop Biotech
Hangzhou Jiuyuan
Huaxin
Triprime
Sinovac
Zhaoke
Kawin
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
The global Recombinant Human Granulocyte Colony-Stimulating market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Recombinant Human Granulocyte Colony-Stimulating volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Recombinant Human Granulocyte Colony-Stimulating market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Recombinant Human Granulocyte Colony-Stimulating Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Others
Segment by Application
Chemotherapy Induced Neutropenia
Before Blood Donation
Stem Cell Transplants
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Amgen
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Kyowa Hakko Kirin
Gensci
Amoytop Biotech
Hangzhou Jiuyuan
Huaxin
Triprime
Sinovac
Zhaoke
Kawin
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
